Nothing Special   »   [go: up one dir, main page]

SI3231801T1 - Bipirazolna sol kot inhibitor JAK - Google Patents

Bipirazolna sol kot inhibitor JAK

Info

Publication number
SI3231801T1
SI3231801T1 SI201431118T SI201431118T SI3231801T1 SI 3231801 T1 SI3231801 T1 SI 3231801T1 SI 201431118 T SI201431118 T SI 201431118T SI 201431118 T SI201431118 T SI 201431118T SI 3231801 T1 SI3231801 T1 SI 3231801T1
Authority
SI
Slovenia
Prior art keywords
bipyrazole
salt
jak inhibitor
jak
inhibitor
Prior art date
Application number
SI201431118T
Other languages
English (en)
Inventor
Yun-Long Li
Jincong Zhuo
Ding-Quan Qian
Song Mei
Ganfeng Cao
Yongchun Pan
Qun Li
Zhongjiang Jia
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of SI3231801T1 publication Critical patent/SI3231801T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201431118T 2013-05-17 2014-05-16 Bipirazolna sol kot inhibitor JAK SI3231801T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17
EP17158350.3A EP3231801B1 (en) 2013-05-17 2014-05-16 Bipyrazole salt as jak inhibitor

Publications (1)

Publication Number Publication Date
SI3231801T1 true SI3231801T1 (sl) 2019-05-31

Family

ID=50983151

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201430239A SI2997023T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot inhibitorji JAK
SI201432046T SI3786162T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci JAK
SI201431118T SI3231801T1 (sl) 2013-05-17 2014-05-16 Bipirazolna sol kot inhibitor JAK
SI201431754T SI3527263T1 (sl) 2013-05-17 2014-05-16 Derivati bipirazola kot zaviralci JAK

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201430239A SI2997023T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot inhibitorji JAK
SI201432046T SI3786162T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci JAK

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201431754T SI3527263T1 (sl) 2013-05-17 2014-05-16 Derivati bipirazola kot zaviralci JAK

Country Status (36)

Country Link
US (8) US9382231B2 (sl)
EP (5) EP3231801B1 (sl)
JP (5) JP6415543B2 (sl)
KR (4) KR102729910B1 (sl)
CN (2) CN105452239B (sl)
AR (2) AR096330A1 (sl)
AU (5) AU2014265279B2 (sl)
BR (1) BR112015028501B8 (sl)
CA (1) CA2911536C (sl)
CL (1) CL2015003355A1 (sl)
CR (2) CR20190156A (sl)
CY (3) CY1119105T1 (sl)
DK (3) DK3786162T3 (sl)
EA (2) EA036448B1 (sl)
ES (4) ES2626793T3 (sl)
FI (1) FI3786162T3 (sl)
HK (1) HK1245769B (sl)
HR (4) HRP20170795T1 (sl)
HU (4) HUE063817T2 (sl)
IL (4) IL242453B (sl)
LT (4) LT3231801T (sl)
ME (2) ME03355B (sl)
MX (2) MX385187B (sl)
MY (1) MY174788A (sl)
PE (2) PE20200527A1 (sl)
PH (2) PH12015502563B1 (sl)
PL (4) PL3786162T3 (sl)
PT (4) PT3231801T (sl)
RS (4) RS56012B1 (sl)
SG (2) SG10201709469SA (sl)
SI (4) SI2997023T1 (sl)
SM (4) SMT202300352T1 (sl)
TR (1) TR201905814T4 (sl)
TW (3) TWI840646B (sl)
UA (1) UA117830C2 (sl)
WO (1) WO2014186706A1 (sl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006326548B2 (en) 2005-12-13 2012-04-05 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
SG10201912675VA (en) 2007-06-13 2020-02-27 Incyte Holdings Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
KR101771401B1 (ko) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서 피라졸­４­일­피롤로［２,３­ｄ］피리미딘 및 피롤­３­일­피롤로［２,３­ｄ］피리미딘의 Ｎ­(헤테로)아릴­피롤리딘 유도체
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PL3050882T3 (pl) 2010-03-10 2018-08-31 Incyte Holdings Corporation Piperydyn-4-ylowe pochodne azetydyny jako inhibitory JAK1
HRP20160841T1 (hr) 2010-05-21 2016-09-23 Incyte Holdings Corporation Topikalna formulacija za jak inhibitor
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
SMT201900243T1 (it) 2011-09-02 2019-07-11 Incyte Holdings Corp Eterociclilammine come inibitori di pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
KR20150074193A (ko) 2012-11-01 2015-07-01 인사이트 코포레이션 Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
PE20151902A1 (es) 2013-03-06 2015-12-26 Incyte Corp Proceso e intermedios para hacer un inhibidor de jak
SI2997023T1 (sl) * 2013-05-17 2017-07-31 Incyte Corporation Bipirazolni derivati kot inhibitorji JAK
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
EP3110409B1 (en) * 2014-02-28 2018-08-15 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
EP4501409A3 (en) 2014-04-08 2025-05-14 Incyte Holdings Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
TW201625643A (zh) 2014-04-30 2016-07-16 英塞特公司 製備ｊａｋ１抑制劑之方法及其新形式
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
HUE053025T2 (hu) 2015-02-27 2021-06-28 Incyte Corp Sók és eljárások PI3K inhibitor elõállítására
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
HK1248570A1 (zh) * 2015-05-29 2018-10-19 西德奈克西斯公司 D2o穩定化的藥物製劑
SI3371190T1 (sl) 2015-11-06 2022-08-31 Incyte Corporation Heterociklične spojine kot inhibitorji PI3K gama
ES2833955T3 (es) 2016-01-05 2021-06-16 Incyte Corp Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
MA46176A (fr) * 2016-09-06 2019-07-17 Hoffmann La Roche Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci
HRP20211827T1 (hr) 2017-10-18 2022-03-18 Incyte Corporation Kondenzirani derivati imidazola supstituirani s tercijarnim hidroksi skupinama kao inhibitori pi3k-gama
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
EP3773593B1 (en) 2018-03-30 2024-05-15 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US11584961B2 (en) 2018-03-30 2023-02-21 Incyte Corporation Biomarkers for inflammatory skin disease
EP3775923A1 (en) 2018-04-13 2021-02-17 Incyte Corporation Biomarkers for graft-versus-host disease
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN113490484B (zh) 2018-10-31 2024-08-23 因赛特公司 治疗血液疾病的组合疗法
MA54544A (fr) 2018-12-19 2021-10-27 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale
KR20210137087A (ko) 2019-03-05 2021-11-17 인사이트 코포레이션 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
US12203942B2 (en) 2019-10-10 2025-01-21 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
SMT202400509T1 (it) * 2020-06-02 2025-01-14 Incyte Corp Procedimenti di preparazione di un inibitore di jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022040180A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
MX2023002035A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de cinasa janus 1 (jak1).
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
PT4255442T (pt) 2020-12-04 2025-05-19 Incyte Corp Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN114099514A (zh) * 2020-12-29 2022-03-01 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor
KR20240009964A (ko) 2021-05-03 2024-01-23 인사이트 코포레이션 결절성 양진 치료를 위한 jak1 경로 억제제
CN118317946A (zh) 2021-07-12 2024-07-09 因赛特公司 用于制备巴瑞替尼的方法和中间体
TW202419088A (zh) 2022-08-05 2024-05-16 美商英塞特公司 使用ｊａｋ抑制劑之蕁麻疹治療
WO2024192350A1 (en) 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
JPH0515775Y2 (sl) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
JP4959918B2 (ja) 2001-10-30 2012-06-27 ノバルティス アーゲー Ｆｌｔ３レセプター・チロシン・キナーゼ活性インヒビターとしてのスタウロスポリン誘導体
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AU2006326548B2 (en) 2005-12-13 2012-04-05 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
SG10201912675VA (en) 2007-06-13 2020-02-27 Incyte Holdings Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
BRPI0820544A2 (pt) * 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
HUE029767T2 (en) * 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
KR101771401B1 (ko) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서 피라졸­４­일­피롤로［２,３­ｄ］피리미딘 및 피롤­３­일­피롤로［２,３­ｄ］피리미딘의 Ｎ­(헤테로)아릴­피롤리딘 유도체
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
BR112012008267B1 (pt) 2009-10-09 2022-10-04 Incyte Holdings Corporation Derivados hidroxila, ceto e glucuronida de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1- il)-3-ciclopentilpropanonitrila
AU2011217961B2 (en) 2010-02-18 2016-05-05 Incyte Holdings Corporation Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
PL3050882T3 (pl) 2010-03-10 2018-08-31 Incyte Holdings Corporation Piperydyn-4-ylowe pochodne azetydyny jako inhibitory JAK1
SG184870A1 (en) * 2010-04-14 2012-11-29 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
HRP20160841T1 (hr) 2010-05-21 2016-09-23 Incyte Holdings Corporation Topikalna formulacija za jak inhibitor
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
SG192910A1 (en) 2011-02-24 2013-09-30 Massachusetts Inst Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AU2012313094B2 (en) 2011-09-22 2017-02-02 Intervet International B.V. Pyrazole carboxamides as janus kinase inhibitors
AR091079A1 (es) * 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
KR20150074193A (ko) 2012-11-01 2015-07-01 인사이트 코포레이션 Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
PE20151902A1 (es) 2013-03-06 2015-12-26 Incyte Corp Proceso e intermedios para hacer un inhibidor de jak
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
SI2997023T1 (sl) 2013-05-17 2017-07-31 Incyte Corporation Bipirazolni derivati kot inhibitorji JAK
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
EP3110409B1 (en) 2014-02-28 2018-08-15 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
TW201625643A (zh) 2014-04-30 2016-07-16 英塞特公司 製備ｊａｋ１抑制劑之方法及其新形式
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
SG11201704053WA (en) 2014-12-16 2017-06-29 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
SMT202400509T1 (it) 2020-06-02 2025-01-14 Incyte Corp Procedimenti di preparazione di un inibitore di jak1
PT4255442T (pt) 2020-12-04 2025-05-19 Incyte Corp Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo

Also Published As

Publication number Publication date
FI3786162T3 (fi) 2023-10-02
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
EA036448B1 (ru) 2020-11-11
SG11201509180WA (en) 2015-12-30
PH12015502563B1 (en) 2019-04-26
US9382231B2 (en) 2016-07-05
DK3231801T3 (en) 2019-04-15
SG10201709469SA (en) 2017-12-28
AR118120A2 (es) 2021-09-22
KR20220127371A (ko) 2022-09-19
NZ753637A (en) 2020-11-27
US20140343030A1 (en) 2014-11-20
WO2014186706A1 (en) 2014-11-20
JP2022163162A (ja) 2022-10-25
JP7126741B2 (ja) 2022-08-29
AU2020202000A1 (en) 2020-04-09
NZ753638A (en) 2020-11-27
US9926301B2 (en) 2018-03-27
EP2997023A1 (en) 2016-03-23
DK3786162T3 (da) 2023-10-09
PH12015502563A1 (en) 2016-02-22
US20180312492A1 (en) 2018-11-01
IL264409A (en) 2019-02-28
RS58743B1 (sr) 2019-06-28
TWI719401B (zh) 2021-02-21
IL287313B (en) 2022-03-01
BR112015028501B8 (pt) 2023-01-24
ES2626793T3 (es) 2017-07-26
RS64591B1 (sr) 2023-10-31
SMT201700258T1 (it) 2017-07-18
NZ713999A (en) 2020-11-27
CA2911536A1 (en) 2014-11-20
AU2018223058A1 (en) 2018-09-20
US11001571B2 (en) 2021-05-11
PH12018502125A1 (en) 2019-03-25
SMT201900223T1 (it) 2019-07-11
KR102442747B1 (ko) 2022-09-14
ME02763B (me) 2018-01-20
US10435392B2 (en) 2019-10-08
CA2911536C (en) 2021-07-20
CN105452239A (zh) 2016-03-30
AU2020202000B2 (en) 2021-03-11
MX373238B (es) 2020-05-08
IL282644A (en) 2021-06-30
PL2997023T3 (pl) 2017-08-31
HUE033587T2 (hu) 2017-12-28
HUE043573T2 (hu) 2019-08-28
EP3231801A1 (en) 2017-10-18
JP2024105557A (ja) 2024-08-06
JP2021008493A (ja) 2021-01-28
NZ753639A (en) 2020-11-27
IL287313A (en) 2021-12-01
SI2997023T1 (sl) 2017-07-31
CN107698569A (zh) 2018-02-16
MX385187B (es) 2025-03-14
AU2014265279B2 (en) 2018-09-27
KR20240063187A (ko) 2024-05-10
US11905275B2 (en) 2024-02-20
AU2022263454B2 (en) 2024-01-18
SMT202100040T1 (it) 2021-03-15
HUE063817T2 (hu) 2024-01-28
JP2019011364A (ja) 2019-01-24
EP3786162B1 (en) 2023-08-09
US20250206726A1 (en) 2025-06-26
IL242453B (en) 2019-11-28
EP2997023B1 (en) 2017-03-22
TW201940479A (zh) 2019-10-16
CR20150633A (es) 2016-04-05
ME03355B (me) 2019-10-20
EP2997023B9 (en) 2018-06-13
CL2015003355A1 (es) 2016-05-27
US11591318B2 (en) 2023-02-28
CY1123756T1 (el) 2022-05-27
JP2016519147A (ja) 2016-06-30
AU2021202685A1 (en) 2021-05-27
KR102663357B1 (ko) 2024-05-14
HK1245769B (en) 2020-02-07
ES2845210T3 (es) 2021-07-26
AU2021202685B2 (en) 2022-11-17
PT2997023T (pt) 2017-05-31
HRP20170795T1 (hr) 2017-08-25
RS61482B1 (sr) 2021-03-31
TWI664176B (zh) 2019-07-01
JP6415543B2 (ja) 2018-10-31
US20210238168A1 (en) 2021-08-05
KR20210120120A (ko) 2021-10-06
IL264409B (en) 2021-05-31
BR112015028501B1 (pt) 2022-11-01
AU2022263454A1 (en) 2022-12-08
NZ753636A (en) 2020-11-27
EP4275756A3 (en) 2024-02-07
US20240150327A1 (en) 2024-05-09
BR112015028501A2 (pt) 2017-07-25
EP3527263A1 (en) 2019-08-21
UA117830C2 (uk) 2018-10-10
PL3786162T3 (pl) 2024-04-08
CR20190156A (es) 2019-05-16
AU2014265279A1 (en) 2015-11-26
HUE053122T2 (hu) 2021-06-28
ES2720073T3 (es) 2019-07-17
EA202090291A3 (ru) 2020-06-30
CN105452239B (zh) 2017-11-21
IL282644B (en) 2021-10-31
CY1121763T1 (el) 2020-07-31
TW202116320A (zh) 2021-05-01
RS56012B1 (sr) 2017-09-29
MX2020004506A (es) 2021-08-09
CN107698569B (zh) 2020-11-27
MY174788A (en) 2020-05-14
PL3527263T3 (pl) 2021-05-17
HK1221466A1 (en) 2017-06-02
TW201512191A (zh) 2015-04-01
US20160289215A1 (en) 2016-10-06
EP4275756A2 (en) 2023-11-15
SMT202300352T1 (it) 2024-01-10
EP3527263B1 (en) 2020-10-28
PT3527263T (pt) 2021-02-01
PT3786162T (pt) 2023-10-20
TW202432140A (zh) 2024-08-16
JP6775560B2 (ja) 2020-10-28
HRP20210119T1 (hr) 2021-03-05
US12247020B2 (en) 2025-03-11
TR201905814T4 (tr) 2019-05-21
SI3527263T1 (sl) 2021-05-31
KR102341908B1 (ko) 2021-12-23
TWI840646B (zh) 2024-05-01
US20230159501A1 (en) 2023-05-25
EA039660B1 (ru) 2022-02-24
ES2960731T3 (es) 2024-03-06
PE20200527A1 (es) 2020-03-09
EP3786162A1 (en) 2021-03-03
KR102729910B1 (ko) 2024-11-15
PE20160126A1 (es) 2016-02-24
LT3231801T (lt) 2019-08-12
LT2997023T (lt) 2017-06-26
EP3231801B1 (en) 2019-02-13
DK3527263T3 (da) 2021-01-25
EA202090291A2 (ru) 2020-05-31
AR096330A1 (es) 2015-12-23
MX2015015738A (es) 2016-03-16
PT3231801T (pt) 2019-05-24
US20200010456A1 (en) 2020-01-09
KR20160019905A (ko) 2016-02-22
CY1119105T1 (el) 2018-02-14
LT3527263T (lt) 2021-05-10
HRP20190713T1 (hr) 2019-06-14
SI3786162T1 (sl) 2024-02-29
AU2018223058B2 (en) 2020-01-02
HRP20231048T1 (hr) 2023-12-22
EA201592199A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
LT3231801T (lt) Bipirazolo druska, kaip jak slopiklis
GB201304526D0 (en) New compounds
ZA201506156B (en) Novel inhibitors
GB201317609D0 (en) Inhibitor compounds
ZA201506296B (en) 2-acylaminothiazole derivative or salt thereof
GB201304527D0 (en) New compounds
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
IL245452B (en) Salts of Armachol
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201322672D0 (en) New compounds
GB201322678D0 (en) New compounds
GB201304777D0 (en) New compounds
GB201304773D0 (en) New compounds
GB201304780D0 (en) New compounds